3 not yet recruiting, 2 recruiting. 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Not yet recruiting 3, Recruiting 2 |
Follow Adebrelimab: new trials by email Literature Review of Adebrelimab trials Research Report on Adebrelimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer HS-10370, Adebrelimab, Cisplatin - Carcinoma, Non-Small-Cell Lung | Phase 3 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 448 | 2026-10-31 | 2026-09-16 |
| A Study of Perioperative Adebrelimab Plus Chemotherapy Versus Adjuvant Therapy in Patients With Resectable NSCLC Adebrelimab (SHR-1316) + chemotherapy, Adebrelimab - Non-small Cell Lung Cancer (NSCLC) | Phase 3 | Not yet recruiting | West China Hospital | 1088 | 2026-10-31 | 2026-10-26 |
| Adebrelimab Combined with Chemotherapy and Thoracic Radiotherapy for First-line Treatment of ES-SCLC Adebrelimab, Radiation Therapy - Extensive Stage Lung Small Cell Carcinoma | Phase 3 | Not yet recruiting | Jinming Yu | 524 | 2024-12-01 | 2024-11-05 |
| Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer Ascorbic acid, FOLFOX Protocol, Adebrelimab - Colorectal Cancer, Vitamin C | Phase 3 | Recruiting | Fudan University | 400 | 2024-12-01 | 2024-10-24 |
| A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (KYLIN-02) SHR-8068, Adebrelimab, Bevacizumab - Advanced Hepatocellular Carcinoma | Phase 3 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 590 | 2024-10-28 | 2026-09-25 |
Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (1)
Fudan University (1) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (1) · Jinming Yu (1) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (1) · West China Hospital (1)
China (2)